SUTRO BIOPHARMA INC
For the period ended Mar 25, 2024. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 25, 2024 · Filed Mar 25, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Additional Pipeline Development and Collaboration Updates:
Additional Pipeline Development and Collaboration Updates:
Sutro plans to submit an IND for STRO-003, a ROR1-targeting ADC, in 2024.
Sutro plans to submit an IND for STRO-004, a tissue factor-targeting ADC, in 2025.
Sutro continues to seek to maximize the value of its proprietary cell-free platform by working with partners on programs in multiple disease spaces and geographies and has generated from collaborators an aggregate of approximately $854 million in payments through December 31, 2023, including equity investments.
In November 2023, Vaxcyte exercised its option to enter into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract for use under its license agreement with Sutro, including for Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and VAX-31. Upon exercising the option, Vaxcyte paid Sutro $50 million and is obligated to pay Sutro an additional $25 million within six months. Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay Sutro up to an additional $60 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.